跳至主要内容
临床试验/NCT01611610
NCT01611610已完成不适用

Clinical Assessment of Spinal Muscular Atrophy Type II and III

Institut de Myologie, France0 个研究点目标入组 4 人开始时间: 2011年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4
主要终点
Change from baseline in total score of Motor Function Measure at one year

研究概览

简要总结

The aim of this project is to establish a network of clinical teams including the major neuromuscular centers in Europe.

We plan to work together to find the best common outcome measures for the following multicenter therapeutic trials.

详细描述

16 patients (6 ambulant and 10 non ambulant), affected by type II and type III SMA will be enrolled and assessed at baseline and 6 and 12 months later. Non ambulant patients will be assessed using the modified version of the Hammersmith Motor Functional Scale while ambulant patients will be assessed using the extended module of the Hammersmith Motor Functional Scale and timed items, the 6 minute walk and a step activity monitor. All patients will also be assessed using the Motor Function Measure (MFM), that covers the whole range of activities for both ambulant and non ambulant patients. All measures will undergo a process of validation including inter observer reliability. This information will be most valuable for any future trial and will make the groups involved ready to participate to future collaborative studies saving a lot of time on the preliminary aspects (validation, reliability, training) that will be fulfilled by the present study. The study will also provide natural history data for a 12 month period on patients with SMA II and III.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
30 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • for ambulant patients:
  • age between 30 months and 24 years
  • documented SMA diagnosis by genetic tests; Each should also have the determination of the SMN2 copy number
  • able to walk 10 meters without support
  • subject who signed an informed consent- subject affiliated to a social security system
  • Inclusion Criteria non ambulant patients:
  • documented diagnosis of SMA by genetic tests
  • not able to walk 10 meters without support
  • subject affiliated to a social security system
  • subject who signed an informed consent

排除标准

  • Patient who are currently involved in other clinical trials
  • severe intellectual impairment limiting the comprehension of the demanded tasks
  • acute neurologic, inflammatory, infectious, endocrine, orthopedic disease in the month preceding the inclusion
  • chronic neurologic (besides SMA), inflammatory, infectious, endocrine, orthopedic disease which are not a natural consequence of SMA
  • spinal surgery scheduled 6 months before or within 12 months after enrollment
  • pregnant women

结局指标

主要结局

Change from baseline in total score of Motor Function Measure at one year

时间窗: at baseline and one year after

次要结局

  • Change from baseline of Pediatric Quality of Life Inventory Score at one year(at baseline and one year after)

研究者

发起方
Institut de Myologie, France
申办方类型
Other
责任方
Sponsor

相似试验

Clinical Assessment of Spinal Muscular Atrophy Type... | 临床试验